211 research outputs found
The new vertebrate CYP1C family : cloning of new subfamily members and phylogenetic analysis
Author Posting. © The Authors, 2005. This is the author's version of the work. It is posted here by permission of Elsevier B. V. for personal use, not for redistribution. The definitive version was published in Biochemical and Biophysical Research Communications 331 (2005): 1016-1024, doi:10.1016/j.bbrc.2005.03.231.Two novel CYP1 genes from teleost fish constituting a new subfamily have been cloned.
These paralogous sequences are designated CYP1C1 and CYP1C2. Both genes were
initially obtained from untreated scup Stenotomus chrysops tissues by RT-PCR and
RACE. Scup CYP1C1 and CYP1C2 code for 524 and 525 amino acids, respectively, and
share 80-81% identity at the nucleotide and amino acid levels. Orthologues of CYP1C1
and CYP1C2 were identified in genome databases for other fish species, and both
CYP1B1 and CYP1C1 were cloned from zebrafish (Danio rerio). Phylogenetic analysis
shows that CYP1Cs and CYP1Bs constitute a sister clade to the CYP1As. Analysis of
sequence domains likely to have functional significance suggests the two CYP1Cs in
scup may have catalytic functions and/or substrate specificity that differ from each other
and from those of mammalian CYP1Bs or CYP1As. RT-PCR results indicate that
CYP1C1 and CYP1C2 are variously expressed in several scup organs.This work was supported by EPA grant R 827102-01-0 and NIH grants 5 P42-ES07381
and ES04696. JVG is supported by a Ruth L. Kirschstein NRSA Fellowship (F32
ES012794)
Rapid Mapping of Zebrafish Mutations With SNPs and Oligonucleotide Microarrays
Large-scale genetic screens in zebrafish have identified thousands of mutations in hundreds of essential genes. The genetic mapping of these mutations is necessary to link DNA sequences to the gene functions defined by mutant phenotypes.Here, we report two advances that will accelerate the mapping of zebrafish mutations: (1) The construction of a first generation single nucleotide polymorphism (SNP) map of the zebrafish genome comprising 2035 SNPs and 178 small insertions/deletions, and (2) the development of a method for mapping mutations in which hundreds of SNPs can be scored in parallel with an oligonucleotide microarray.We have demonstrated the utility of the microarray technique in crosses with haploid and diploid embryos by mapping two known mutations to their previously identified locations.We have also used this approach to localize four previously unmapped mutations.We expect that mapping with SNPs and oligonucleotide microarrays will accelerate the molecular analysis of zebrafish mutations
Bay Breeze Influence on Surface Ozone at Edgewood, MD During July 2011
Surface ozone (O3) was analyzed to investigate the role of the bay breeze on air quality at two locations in Edgewood, Maryland (lat: 39.4deg, lon: 76.3deg) for the month of July 2011. Measurements were taken as part of the first year of NASA's "Deriving Information on Surface Conditions from Column and Vertically Resolved Observations Relevant to Air Quality" (DISCOVER-AQ) Earth Venture campaign and as part of NASA's Geostationary for Coastal and Air Pollution Events Chesapeake Bay Oceanographic campaign with DISCOVER-AQ (Geo-CAPE CBODAQ). Geo-CAPE CBODAQ complements DISCOVER-AQ by providing ship-based observations over the Chesapeake Bay. A major goal of DISCOVER-AQ is determining the relative roles of sources, photochemistry and local meteorology during air quality events in the Mid-Atlantic region of the U.S. Surface characteristics, transport and vertical structures of O3 during bay breezes were identified using in-situ surface, balloon and aircraft data, along with remote sensing equipment. Localized late day peaks in O3 were observed during bay breeze days, maximizing an average of 3 h later compared to days without bay breezes. Of the 10 days of July 2011 that violated the U.S. Environmental Protection Agency (EPA) 8 h O3 standard of 75 parts per billion by volume (ppbv) at Edgewood, eight exhibited evidence of a bay breeze circulation. The results indicate that while bay breezes and the processes associated with them are not necessary to cause exceedances in this area, bay breezes exacerbate poor air quality that sustains into the late evening hours at Edgewood. The vertical and horizontal distributions of O3 from the coastal Edgewood area to the bay also show large gradients that are often determined by boundary layer stability. Thus, developing air quality models that can sufficiently resolve these dynamics and associated chemistry, along with more consistent monitoring of O3 and meteorology on and along the complex coastline of Chesapeake Bay must be a high priority
Biophysical and electrochemical studies of protein-nucleic acid interactions
This review is devoted to biophysical and electrochemical methods used for studying protein-nucleic acid (NA) interactions. The importance of NA structure and protein-NA recognition for essential cellular processes, such as replication or transcription, is discussed to provide background for description of a range of biophysical chemistry methods that are applied to study a wide scope of protein-DNA and protein-RNA complexes. These techniques employ different detection principles with specific advantages and limitations and are often combined as mutually complementary approaches to provide a complete description of the interactions. Electrochemical methods have proven to be of great utility in such studies because they provide sensitive measurements and can be combined with other approaches that facilitate the protein-NA interactions. Recent applications of electrochemical methods in studies of protein-NA interactions are discussed in detail
High Performance In Vivo Near-IR (>1 {\mu}m) Imaging and Photothermal Cancer Therapy with Carbon Nanotubes
Short single-walled carbon nanotubes (SWNTs) functionalized by PEGylated
phospholipids are biologically non-toxic and long-circulating nanomaterials
with intrinsic near infrared photoluminescence (NIR PL), characteristic Raman
spectra, and strong optical absorbance in the near infrared (NIR). This work
demonstrates the first dual application of intravenously injected SWNTs as
photoluminescent agents for in vivo tumor imaging in the 1.0-1.4 {\mu}m
emission region and as NIR absorbers and heaters at 808 nm for photothermal
tumor elimination at the lowest injected dose (70 {\mu}g of SWNT/mouse,
equivalent to 3.6 mg/kg) and laser irradiation power (0.6 W/cm2) reported to
date. Ex vivo resonance Raman imaging revealed the SWNT distribution within
tumors at a high spatial resolution. Complete tumor elimination was achieved
for large numbers of photothermally treated mice without any toxic side effects
after more than six months post-treatment. Further, side-by-side experiments
were carried out to compare the performance of SWNTs and gold nanorods (AuNRs)
at an injected dose of 700 {\mu}g of AuNR/mouse (equivalent to 35 mg/kg) in NIR
photothermal ablation of tumors in vivo. Highly effective tumor elimination
with SWNTs was achieved at 10 times lower injected doses and lower irradiation
powers than for AuNRs. These results suggest there are significant benefits of
utilizing the intrinsic properties of biocompatible SWNTs for combined cancer
imaging and therapy.Comment: Nanoresearch, in pres
Epigenetic and Genetic Factors Predict Women's Salivary Cortisol following a Threat to the Social Self
10.1371/journal.pone.0048597PLoS ONE711
Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trial
<p>Abstract</p> <p>Background</p> <p>Overweight and obesity are highly prevalent among persons with serious mental illness. These conditions likely contribute to premature cardiovascular disease and a 20 to 30 percent shortened life expectancy in this vulnerable population. Persons with serious mental illness need effective, appropriately tailored behavioral interventions to achieve and maintain weight loss. Psychiatric rehabilitation day programs provide logical intervention settings because mental health consumers often attend regularly and exercise can take place on-site. This paper describes the Randomized Trial of Achieving Healthy Lifestyles in Psychiatric Rehabilitation (ACHIEVE). The goal of the study is to determine the effectiveness of a behavioral weight loss intervention among persons with serious mental illness that attend psychiatric rehabilitation programs. Participants randomized to the intervention arm of the study are hypothesized to have greater weight loss than the control group.</p> <p>Methods/Design</p> <p>A targeted 320 men and women with serious mental illness and overweight or obesity (body mass index ≥ 25.0 kg/m<sup>2</sup>) will be recruited from 10 psychiatric rehabilitation programs across Maryland. The core design is a randomized, two-arm, parallel, multi-site clinical trial to compare the effectiveness of an 18-month behavioral weight loss intervention to usual care. Active intervention participants receive weight management sessions and physical activity classes on-site led by study interventionists. The intervention incorporates cognitive adaptations for persons with serious mental illness attending psychiatric rehabilitation programs. The initial intensive intervention period is six months, followed by a twelve-month maintenance period in which trained rehabilitation program staff assume responsibility for delivering parts of the intervention. Primary outcomes are weight loss at six and 18 months.</p> <p>Discussion</p> <p>Evidence-based approaches to the high burden of obesity and cardiovascular disease risk in person with serious mental illness are urgently needed. The ACHIEVE Trial is tailored to persons with serious mental illness in community settings. This multi-site randomized clinical trial will provide a rigorous evaluation of a practical behavioral intervention designed to accomplish and sustain weight loss in persons with serious mental illness.</p> <p>Trial Registration</p> <p>Clinical Trials.gov NCT00902694</p
Acupuncture and chiropractic care for chronic pain in an integrated health plan: a mixed methods study
<p>Abstract</p> <p>Background</p> <p>Substantial recent research examines the efficacy of many types of complementary and alternative (CAM) therapies. However, outcomes associated with the "real-world" use of CAM has been largely overlooked, despite calls for CAM therapies to be studied in the manner in which they are practiced. Americans seek CAM treatments far more often for chronic musculoskeletal pain (CMP) than for any other condition. Among CAM treatments for CMP, acupuncture and chiropractic (A/C) care are among those with the highest acceptance by physician groups and the best evidence to support their use. Further, recent alarming increases in delivery of opioid treatment and surgical interventions for chronic pain--despite their high costs, potential adverse effects, and modest efficacy--suggests the need to evaluate real world outcomes associated with promising non-pharmacological/non-surgical CAM treatments for CMP, which are often well accepted by patients and increasingly used in the community.</p> <p>Methods/Design</p> <p>This multi-phase, mixed methods study will: (1) conduct a retrospective study using information from electronic medical records (EMRs) of a large HMO to identify unique clusters of patients with CMP (e.g., those with differing demographics, histories of pain condition, use of allopathic and CAM health services, and comorbidity profiles) that may be associated with different propensities for A/C utilization and/or differential outcomes associated with such care; (2) use qualitative interviews to explore allopathic providers' recommendations for A/C and patients' decisions to pursue and retain CAM care; and (3) prospectively evaluate health services/costs and broader clinical and functional outcomes associated with the receipt of A/C relative to carefully matched comparison participants receiving traditional CMP services. Sensitivity analyses will compare methods relying solely on EMR-derived data versus analyses supplementing EMR data with conventionally collected patient and clinician data.</p> <p>Discussion</p> <p>Successful completion of these aggregate aims will provide an evaluation of outcomes associated with the real-world use of A/C services. The trio of retrospective, qualitative, and prospective study will also provide a clearer understanding of the decision-making processes behind the use of A/C for CMP and a transportable methodology that can be applied to other health care settings, CAM treatments, and clinical populations.</p> <p>Trial registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01345409">NCT01345409</a></p
Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).
Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)
Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)
- …